Nobuhisa Terada, MDa, Akiyoshi Konno, MDb, Kiyoshi Togawa, MDa

Slides:

Advertisements

Similar presentations

Nasal challenge with allergen leads to maxillary sinus inflammation

Advertisements

Assessment of inflammation in noninfectious chronic maxillary sinusitis Pascal Demoly, MDa, Louis Crampette, MDb, Michel Mondain, MDb, Alison M. Campbell,

A critical role of IL-33 in experimental allergic rhinitis

F.Estelle R. Simons, MDa, Bruce M. Prenner, MDb, Albert Finn, MDc

Different expression of cytokine and membrane molecules by circulating lymphocytes on acute mental stress in patients with atopic dermatitis in comparison.

Eosinophil cationic protein and histamine after intestinal challenge in patients with cow's milk intolerance Ulf Bengtsson, MD, PhDa, Tina W. Knutson,

IL-25 as a novel therapeutic target in nasal polyps of patients with chronic rhinosinusitis Hyun-Woo Shin, MD, PhD, Dong-Kyu Kim, MD, Min-Hyun Park, MD,

Predominance of type 2 cytokine–producing CD4+ and CD8+ cells in patients with atopic dermatitis Masatoshi Nakazawa, DVMa, Nakako Sugi, MDb, Hiroshi.

Effect of interleukin-5 and granulocyte-macrophage colony stimulating factor on in vitro eosinophil function: Comparison with airway eosinophils Julie.

Evidence for a role for IL-5 and eotaxin in activating and recruiting eosinophils in drug- induced cutaneous eruptions Nikhil Yawalkar, MD, Maithili Shrikhande,

Hong Wei Chu, MDa, Monica Kraft, MDa, James E. Krause, PhDb, Michael D

Comparison of once-daily ebastine 20 mg, ebastine 10 mg, loratadine 10 mg, and placebo in the treatment of seasonal allergic rhinitis Paul H. Ratner,

Expression of 11β-hydroxysteroid dehydrogenase 1 and 2 in patients with chronic rhinosinusitis and their possible contribution to local glucocorticoid.

Deposition of eosinophil-granule major basic protein and expression of intercellular adhesion molecule-1 and vascular cell adhesion molecule-1 in the.

Pathophysiology of severe asthma

Suppression of antigen-specific T- and B-cell responses by intranasal or oral administration of recombinant Bet v 1, the major birch pollen allergen,

Comparison of the efficacy of budesonide and fluticasone propionate aqueous nasal spray for once daily treatment of perennial allergic rhinitis James.

As-needed use of fluticasone propionate nasal spray reduces symptoms of seasonal allergic rhinitis Albert Jen, MD, Fuad Baroody, MD, Marcy de Tineo,

Mechanism of neutrophil recruitment induced by IL-8 in chronic sinusitis Hideaki Suzuki, MDa, Yuichi Takahashi, MDb, Hideya Wataya, MDa,c, Katsuhisa Ikeda,

Requirements for allergen-induced airway inflammation and hyperreactivity in CD4- deficient and CD4-sufficient HLA-DQ transgenic mice Svetlana P. Chapoval,

Selective early increases of bronchoalveolar CD8+ lymphocytes in a LEW rat model of hypersensitivity pneumonitis Hal B. Richerson, MD, J.Daniel Coon,

Critical role of IgE-dependent mast cell activation in a murine model of allergic conjunctivitis Ken Fukuda, MD, PhD, Masaharu Ohbayashi, PhD, Kei Morohoshi,

Serum levels of eosinophil cationic protein in allergic diseases and natural allergen exposure Margherita Tomassini, MDa, Laura Magrini, MDa, Guido De.

Topical azelastine reduces eosinophil activation and intercellular adhesion molecule-1 expression on nasal epithelial cells: An antiallergic activity

Chronologic analysis of in situ cytokine expression in mite allergen-induced dermatitis in atopic subjects Nobuo Yamada, MDa, Motoshi Wakugawa, MDa,

Stem cell factor in nasal polyposis and allergic rhinitis: Increased expression by structural cells is suppressed by in vivo topical corticosteroids

Expression and localization of histamine H2 receptor messenger RNA in human nasal mucosa Noriko Hirata, MDa, Kazuhiko Takeuchi, MDa, Kotaro Ukai, MDa,

Rhinophototherapy: A new therapeutic tool for the management of allergic rhinitis Andrea I. Koreck, MD, PhD, Zsanett Csoma, MD, Laszlo Bodai, Ferenc Ignacz,

Evidence for expression of eosinophil-associated IL-12 messenger RNA and immunoreactivity in bronchial asthma Esra Nutku, MDa, Abdelilah Soussi Gounni,

Pathophysiology of the inflammatory response

Basophils and eosinophils in allergic rhinitis

Inflammatory cell and epithelial characteristics of perennial allergic and nonallergic rhinitis with a symptom history of 1 to 3 years’ duration Kawa.

IL-12 affects Dermatophagoides farinae–induced IL-4 production by T cells from pediatric patients with mite-sensitive asthma Takeshi Noma, MD, PhD, Izumi.

Subjective and objective assessments in patients with seasonal allergic rhinitis: Effects of therapy with mometasone furoate nasal spray Eli O. Meltzer,

Ganglioside GQ1b enhances Ig production by human PBMCs

F.Estelle R. Simons, MDa, Bruce M. Prenner, MDb, Albert Finn, MDc

IL-25 as a novel therapeutic target in nasal polyps of patients with chronic rhinosinusitis Hyun-Woo Shin, MD, PhD, Dong-Kyu Kim, MD, Min-Hyun Park, MD,

Cutaneous inflammatory cell infiltrate in chronic idiopathic urticaria: Comparison of patients with and without anti-FcϵRI or anti-IgE autoantibodies

IL-9 expression by human eosinophils: Regulation by IL-1β and TNF-α

Increased expression of the CD80 accessory molecule by alveolar macrophages in asthmatic subjects and its functional involvement in allergen presentation.

Basophil and eosinophil accumulation and mast cell degranulation in the nasal mucosa of patients with hay fever after local allergen provocation Alex.

Effect of rush immunotherapy on airway inflammation and airway hyperresponsiveness after bronchoprovocation with allergen in asthma Yasurou Kohno, MDa,

TH1/TH2 cytokines and inflammatory cells in skin biopsy specimens from patients with chronic idiopathic urticaria: Comparison with the allergen-induced.

Assessment of inflammation in noninfectious chronic maxillary sinusitis Pascal Demoly, MDa, Louis Crampette, MDb, Michel Mondain, MDb, Alison M. Campbell,

A randomized, double-blind trial of the effect of treatment with montelukast on bronchial hyperresponsiveness and serum eosinophilic cationic protein.

Potential role of interleukin-1 in allergen-induced late asthmatic reactions in guinea pigs: Suppressive effect of interleukin-1 receptor antagonist on.

Harald Renz, MD, Chaya Brodie, PhD, Katherine Bradley, BS, Donald Y. M

Molecular pathology of allergic disease

Allergic rhinitis Journal of Allergy and Clinical Immunology

Ajay B. Antony, HSa, Robert S. Tepper, MDb, Kamal A. Mohammed, PhDa

Chemokines in seasonal allergic rhinitis

Delayed eosinophil apoptosis in asthma

The effects of IL-5 on airway physiology and inflammation in rats

Nasal inflammatory mediators and specific IgE production after nasal challenge with grass pollen in local allergic rhinitis Carmen Rondón, MD, PhD, Javier.

Intranasal administration of eotaxin increases nasal eosinophils and nitric oxide in patients with allergic rhinitis Toyoyuki Hanazawa, MD, PhD, Julio.

Chemical constituents of diesel exhaust particles induce IL-4 production and histamine release by human basophils Gilles Devouassoux, MDa, Andrew Saxon,

Grass pollen immunotherapy: IL-10 induction and suppression of late responses precedes IgG4 inhibitory antibody activity James N. Francis, PhD, Louisa.

Alvaro A. Cruz, MD, Robert M

Suplatast tosilate inhibits goblet-cell metaplasia of airway epithelium in sensitized mice Jae Jeong Shim, MD, Karim Dabbagh, PhD, Kiyoshi Takeyama, MD,

Rame A. Taha, MDa, Eleanor M. Minshall, PhDa, Donald Y. M

Monocyte chemotactic proteins in allergen-induced inflammation in the nasal mucosa: Effect of topical corticosteroids Pota Christodoulopoulos, BSca,

Abnormalities of cell and mediator levels in bronchoalveolar lavage fluid of patients with mild asthma Sally E. Wenzel, MD Journal of Allergy and Clinical.

Nasal challenge with allergen leads to maxillary sinus inflammation

Identification of IL-16 as the lymphocyte chemotactic activity in the bronchoalveolar lavage fluid of histamine-challenged asthmatic patients Margaret.

IL-4 upregulates FcϵRI α-chain messenger RNA in eosinophils

IL-4– and IL-5–positive T lymphocytes, eosinophils, and mast cells in allergen-induced late-phase cutaneous reactions in atopic subjects Luis T. Barata,

Comparison of ciliary activity and inflammatory mediator release from bronchial epithelial cells of nonatopic nonasthmatic subjects and atopic asthmatic.

Mechanism of topical glucocorticoid treatment of hay fever: IL-5 and eosinophil activation during natural allergen exposure are suppressed, but IL-4,

Levocetirizine better protects than desloratadine in a nasal provocation with allergen Cédric Deruaz, MD, Annette Leimgruber, MD, Monika Berney, Estelle.

Annette M. Colavita, MD, Annette T. Hastie, PhD, Ali I

Presentation transcript:

Biochemical properties of eosinophils and their preferential accumulation mechanism in nasal allergy Nobuhisa Terada, MDa, Akiyoshi Konno, MDb, Kiyoshi Togawa, MDa Journal of Allergy and Clinical Immunology Volume 94, Issue 3, Pages 629-642 (September 1994) DOI: 10.1016/0091-6749(94)90140-6 Copyright © 1994 Mosby, Inc. Terms and Conditions

FIG. 1 Time schedule for study. Journal of Allergy and Clinical Immunology 1994 94, 629-642DOI: (10.1016/0091-6749(94)90140-6) Copyright © 1994 Mosby, Inc. Terms and Conditions

FIG. 2 Changes in nasal symptoms after antigen challenge. A, Frequency of sneezing. B, Amount of nasal discharge. C, Percentage change in NAR. Vertical bars mean ± SE. Asterisks indicate significant change at each hour compared with baseline wash (0) performed before antigen challenge. Journal of Allergy and Clinical Immunology 1994 94, 629-642DOI: (10.1016/0091-6749(94)90140-6) Copyright © 1994 Mosby, Inc. Terms and Conditions

FIG. 2 Changes in nasal symptoms after antigen challenge. A, Frequency of sneezing. B, Amount of nasal discharge. C, Percentage change in NAR. Vertical bars mean ± SE. Asterisks indicate significant change at each hour compared with baseline wash (0) performed before antigen challenge. Journal of Allergy and Clinical Immunology 1994 94, 629-642DOI: (10.1016/0091-6749(94)90140-6) Copyright © 1994 Mosby, Inc. Terms and Conditions

FIG. 2 Changes in nasal symptoms after antigen challenge. A, Frequency of sneezing. B, Amount of nasal discharge. C, Percentage change in NAR. Vertical bars mean ± SE. Asterisks indicate significant change at each hour compared with baseline wash (0) performed before antigen challenge. Journal of Allergy and Clinical Immunology 1994 94, 629-642DOI: (10.1016/0091-6749(94)90140-6) Copyright © 1994 Mosby, Inc. Terms and Conditions

FIG. 3 Changes in inflammatory cell counts in nasal lavage fluids. Eosinophils in precipitate were counted in a cell counting plates after staining with Hinkelman's stain, whereas basophilic and mononuclear cells were counted after staining with Osada-Tatai stain and Türk stain, respectively. MNCs, Mononuclear cells; basophils, basophilic cells. Journal of Allergy and Clinical Immunology 1994 94, 629-642DOI: (10.1016/0091-6749(94)90140-6) Copyright © 1994 Mosby, Inc. Terms and Conditions

FIG. 4 Changes in levels of chemical mediators in nasal lavage fluids. Vertical bars mean ± SE. Asterisks indicate significant change at each hour compared with baseline wash (0) performed before antigen challenge. Journal of Allergy and Clinical Immunology 1994 94, 629-642DOI: (10.1016/0091-6749(94)90140-6) Copyright © 1994 Mosby, Inc. Terms and Conditions

FIG. 5 Changes in percentage of EG2-positive eosinophils. Although incidence of EG2 positive was 19.5% before challenge, it increased to 42.0% at 8 hours, 47.5% at 10 hours, and 47.5% at 12 hours. Vertical bars mean ± SE. Asterisks indicate significant change at each hour compared with baseline wash (0) performed before antigen challenge. Journal of Allergy and Clinical Immunology 1994 94, 629-642DOI: (10.1016/0091-6749(94)90140-6) Copyright © 1994 Mosby, Inc. Terms and Conditions

FIG. 6 Changes in amount of ECP. Amount of ECP increased during both early and late phases but more markedly during late phase. Vertical bars mean ± SE. Asterisks indicate significant change at each hour compared with baseline wash (0) performed before antigen challenge. Journal of Allergy and Clinical Immunology 1994 94, 629-642DOI: (10.1016/0091-6749(94)90140-6) Copyright © 1994 Mosby, Inc. Terms and Conditions

FIG. 7 Number of activated eosinophils and ECP amount are compared between seven patients with late phase response and seven patients without marked late phase response. Values are mean ± SE. Both number of activated eosinophils and amount of ECP showed a tendency to increase in positive group. Journal of Allergy and Clinical Immunology 1994 94, 629-642DOI: (10.1016/0091-6749(94)90140-6) Copyright © 1994 Mosby, Inc. Terms and Conditions

FIG. 8 Changes in histamine threshold after antigen challenge. Journal of Allergy and Clinical Immunology 1994 94, 629-642DOI: (10.1016/0091-6749(94)90140-6) Copyright © 1994 Mosby, Inc. Terms and Conditions

FIG. 9 Immunostaining patterns in nasal mucosa. (Original magnification ×200.) Eosinophils were identified with monoclonal antibody BMK-13. A, Control nasal mucosa exposed to 100 μl PBS containing 0.1% bovin serum albumin. B, Nasal mucosa exposed to 100 μl 10 μg/ml rhIL-5. Journal of Allergy and Clinical Immunology 1994 94, 629-642DOI: (10.1016/0091-6749(94)90140-6) Copyright © 1994 Mosby, Inc. Terms and Conditions

FIG. 10 A, Number of eosinophils and amount of ECP in nasal lavage fluids before and after application of rhIL-5 and PBS. Values are mean ± SE. B, Amount of sIgA, IgA, IgG, and IgM in nasal lavage fluids before and after application of rhIL-5 and PBS. Values are mean ± SE. Journal of Allergy and Clinical Immunology 1994 94, 629-642DOI: (10.1016/0091-6749(94)90140-6) Copyright © 1994 Mosby, Inc. Terms and Conditions

FIG. 10 A, Number of eosinophils and amount of ECP in nasal lavage fluids before and after application of rhIL-5 and PBS. Values are mean ± SE. B, Amount of sIgA, IgA, IgG, and IgM in nasal lavage fluids before and after application of rhIL-5 and PBS. Values are mean ± SE. Journal of Allergy and Clinical Immunology 1994 94, 629-642DOI: (10.1016/0091-6749(94)90140-6) Copyright © 1994 Mosby, Inc. Terms and Conditions

FIG. 11 Changes in amount of IL-5 in nasal lavage fluids before and after antigen challenge. Amount of IL-5 represents 40 ml of nasal lavage fluid. Vertical bars mean ± SE. Journal of Allergy and Clinical Immunology 1994 94, 629-642DOI: (10.1016/0091-6749(94)90140-6) Copyright © 1994 Mosby, Inc. Terms and Conditions

FIG. 12 Comparison of total number of eosinophils in nasal lavage fluids in IL-5–positive group, IL-5–negative group, and group in whom antigen challenge was not carried out. Total number of eosinophils in IL-5–positive group was higher than that in IL-5–negative group. Values are mean ± SE. Journal of Allergy and Clinical Immunology 1994 94, 629-642DOI: (10.1016/0091-6749(94)90140-6) Copyright © 1994 Mosby, Inc. Terms and Conditions

FIG. 13 Effect of rhIL-5 in ICAM-1 mRNA expression in nasal mucosa with nasal allergy and with nonallergic rhinitis. Asterisk indicates significant increase compared with unstimulated ICAM-1 mRNA expression in absence of rhIL-5 (p < 0.01). Journal of Allergy and Clinical Immunology 1994 94, 629-642DOI: (10.1016/0091-6749(94)90140-6) Copyright © 1994 Mosby, Inc. Terms and Conditions

FIG. 14 Serum level of sICAM-1 subjects with nasal allergy and normal individuals. Values are mean ± SD. Journal of Allergy and Clinical Immunology 1994 94, 629-642DOI: (10.1016/0091-6749(94)90140-6) Copyright © 1994 Mosby, Inc. Terms and Conditions

FIG. 15 Inhibitory effect of anti–VLA-4 monoclonal antibody on inflammatory cell infiltration in nasal mucosa caused by antigen challenge. Asterisk indicates significant change compared with untreated nasal mucosa. *p < 0.05, **p < 0.01. Values are mean ± SE. Journal of Allergy and Clinical Immunology 1994 94, 629-642DOI: (10.1016/0091-6749(94)90140-6) Copyright © 1994 Mosby, Inc. Terms and Conditions

FIG. 15 Inhibitory effect of anti–VLA-4 monoclonal antibody on inflammatory cell infiltration in nasal mucosa caused by antigen challenge. Asterisk indicates significant change compared with untreated nasal mucosa. *p < 0.05, **p < 0.01. Values are mean ± SE. Journal of Allergy and Clinical Immunology 1994 94, 629-642DOI: (10.1016/0091-6749(94)90140-6) Copyright © 1994 Mosby, Inc. Terms and Conditions